Sanofi, Regeneron Expand DUPIXENT Alliance in Deal Worth Up to €8 Billion
The companies will split development costs and future profits evenly as the pact adds four early-stage antibody drugs targeting immunological diseases.
- On Thursday, Sanofi and Regeneron Pharmaceuticals announced an expanded partnership including a $1 billion upfront payment and up to $7 billion in milestone payments to develop four new antibody drugs.
- The four antibody drugs target the same type 2 inflammation pathways as Dupixent, with REGN20423 currently in early-stage testing for atopic dermatitis and three others expected to begin clinical testing in 2027.
- Regeneron will lead research and development while Sanofi spearheads global sales efforts; the companies will share costs equally and split future Profits from these potential products.
- The agreement marks an early success for CEO Belen Garijo, who took Sanofi's top role in May; the deal also settles litigation and addresses investor concerns regarding Dupixent's patent expiration.
- Jefferies analyst Michael Leuchten described the expansion as a positive signal of Sanofi's proactive focus on addressing key investor uncertainties and demonstrating speed of progress in immunology.
22 Articles
22 Articles
DECRYPTAGE - The French laboratory, which has to replenish its portfolio of medicines, spends up to €8 billion.
Sanofi, Regeneron Expand DUPIXENT Alliance in Deal Worth Up to €8 Billion
Regeneron and Sanofi (NASDAQ:SNY) announced an expanded collaboration focused on developing next-generation medicines for type 2 inflammatory diseases, extending an alliance that has produced the blockbuster therapy DUPIXENT. Under the agreement, Regeneron will contribute four long-acting, fully hu
Pharmacists Sanofi and Regeneron have concluded an agreement to expand their strategic alliance in the co-development and global marketing of new immunology drugs, in a transaction with a potential value of up to US$ 8 billion for the American partner. Exclusive material for subscribers. To have full access, access the link of the material and register.
Coverage Details
Bias Distribution
- 62% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
